These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 12920388)

  • 1. Reboxetine and citalopram in panic disorder: a single-blind, cross-over, flexible-dose pilot study.
    Seedat S; van Rheede van Oudtshoorn E; Muller JE; Mohr N; Stein DJ
    Int Clin Psychopharmacol; 2003 Sep; 18(5):279-84. PubMed ID: 12920388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The efficacy of reboxetine in the treatment-refractory patients with panic disorder: an open label study.
    Dannon PN; Iancu I; Grunhaus L
    Hum Psychopharmacol; 2002 Oct; 17(7):329-33. PubMed ID: 12415550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of the selective monoamine reuptake inhibitors reboxetine and citalopram on visually-evoked event-related potentials in depressed patients.
    Hetzel G; Moeller O; Erfurth A; Michael N; Rothermundt M; Arolt V; Evers S
    Pharmacopsychiatry; 2004 Sep; 37(5):200-5. PubMed ID: 15470798
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diminished neural processing of aversive and rewarding stimuli during selective serotonin reuptake inhibitor treatment.
    McCabe C; Mishor Z; Cowen PJ; Harmer CJ
    Biol Psychiatry; 2010 Mar; 67(5):439-45. PubMed ID: 20034615
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Different gender response to serotonergic and noradrenergic antidepressants. A comparative study of the efficacy of citalopram and reboxetine.
    Berlanga C; Flores-Ramos M
    J Affect Disord; 2006 Oct; 95(1-3):119-23. PubMed ID: 16782204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential prediction of first clinical response to serotonergic and noradrenergic antidepressants using the loudness dependence of auditory evoked potentials in patients with major depressive disorder.
    Juckel G; Pogarell O; Augustin H; Mulert C; Müller-Siecheneder F; Frodl T; Mavrogiorgou P; Hegerl U
    J Clin Psychiatry; 2007 Aug; 68(8):1206-12. PubMed ID: 17854244
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the treatment with paroxetine and reboxetine in panic disorder: a randomized, single-blind study.
    Bertani A; Perna G; Migliarese G; Di Pasquale D; Cucchi M; Caldirola D; Bellodi L
    Pharmacopsychiatry; 2004 Sep; 37(5):206-10. PubMed ID: 15359375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of the response to citalopram and reboxetine in post-stroke depressed patients.
    Rampello L; Chiechio S; Nicoletti G; Alvano A; Vecchio I; Raffaele R; Malaguarnera M
    Psychopharmacology (Berl); 2004 Apr; 173(1-2):73-8. PubMed ID: 14685645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized double-blind comparison of serotonergic (Citalopram) versus noradrenergic (Reboxetine) reuptake inhibitors in outpatients with somatoform, DSM-IV-TR pain disorder.
    Aragona M; Bancheri L; Perinelli D; Tarsitani L; Pizzimenti A; Conte A; Inghilleri M
    Eur J Pain; 2005 Feb; 9(1):33-8. PubMed ID: 15629872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Citalopram plus reboxetine in treatment-resistant depression.
    Devarajan S; Dursun SM
    Can J Psychiatry; 2000 Jun; 45(5):489-90. PubMed ID: 10900531
    [No Abstract]   [Full Text] [Related]  

  • 11. Reboxetine, a selective norepinephrine reuptake inhibitor, is an effective and well-tolerated treatment for panic disorder.
    Versiani M; Cassano G; Perugi G; Benedetti A; Mastalli L; Nardi A; Savino M
    J Clin Psychiatry; 2002 Jan; 63(1):31-7. PubMed ID: 11838623
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Basal prolactin values correlate with response to reboxetine treatment in major depression, but not with response to citalopram.
    Moeller O; Hetzel G; Michael N; Rothermundt M; Arolt V; Erfurth A
    Neuropsychobiology; 2005; 51(2):67-71. PubMed ID: 15741746
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Severity of depression and response to antidepressants: GENPOD randomised controlled trial.
    Wiles NJ; Mulligan J; Peters TJ; Cowen PJ; Mason V; Nutt D; Sharp D; Tallon D; Thomas L; O'Donovan MC; Lewis G
    Br J Psychiatry; 2012 Feb; 200(2):130-6. PubMed ID: 22194183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical efficacy of reboxetine in major depression.
    Schatzberg AF
    J Clin Psychiatry; 2000; 61 Suppl 10():31-8. PubMed ID: 10910015
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic effects of escitalopram and reboxetine in seasonal affective disorder: a pooled analysis.
    Pjrek E; Konstantinidis A; Assem-Hilger E; Praschak-Rieder N; Willeit M; Kasper S; Winkler D
    J Psychiatr Res; 2009 May; 43(8):792-7. PubMed ID: 19230909
    [TBL] [Abstract][Full Text] [Related]  

  • 16. No effects of antidepressants on negative symptoms in schizophrenia.
    Hinkelmann K; Yassouridis A; Kellner M; Jahn H; Wiedemann K; Raedler TJ
    J Clin Psychopharmacol; 2013 Oct; 33(5):686-90. PubMed ID: 23857309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sex differences in depressive symptoms and tolerability after treatment with selective serotonin reuptake inhibitor antidepressants: Secondary analyses of the GENPOD trial.
    Gougoulaki M; Lewis G; Nutt DJ; Peters TJ; Wiles NJ; Lewis G
    J Psychopharmacol; 2021 Aug; 35(8):919-927. PubMed ID: 33637001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The norepinephrine reuptake inhibitor reboxetine is more potent in treating murine narcoleptic episodes than the serotonin reuptake inhibitor escitalopram.
    Schmidt C; Leibiger J; Fendt M
    Behav Brain Res; 2016 Jul; 308():205-10. PubMed ID: 27118715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence for modulation of facial emotional processing bias during emotional expression decoding by serotonergic and noradrenergic antidepressants: an event-related potential (ERP) study.
    Kerestes R; Labuschagne I; Croft RJ; O'Neill BV; Bhagwagar Z; Phan KL; Nathan PJ
    Psychopharmacology (Berl); 2009 Mar; 202(4):621-34. PubMed ID: 18825371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nicotine, but not mecamylamine, enhances antidepressant-like effects of citalopram and reboxetine in the mouse forced swim and tail suspension tests.
    Andreasen JT; Redrobe JP
    Behav Brain Res; 2009 Jan; 197(1):150-6. PubMed ID: 18786574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.